OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+35.52%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$376M
AUM Growth
+$376M
(+22%)
Cap. Flow
+$4M
Cap. Flow
% of AUM
1.06%
Top 10 Holdings %
Top 10 Hldgs %
62.6%
Holding
53
New
13
Increased
11
Reduced
14
Closed
8
Top Buys
| 1 |
Arvinas
ARVN
|
$10.9M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
$6.33M |
| 3 |
Codexis
CDXS
|
$5.88M |
| 4 |
TG Therapeutics
TGTX
|
$5.55M |
| 5 |
Relmada Therapeutics
RLMD
|
$3.51M |
Top Sells
| 1 |
MOR
MorphoSys AG American Depositary Shares
MOR
|
$10.5M |
| 2 |
Biohaven
BHVN
|
$10.2M |
| 3 |
TELA Bio
TELA
|
$6M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$4.29M |
| 5 |
Geron
GERN
|
$4.06M |
Sector Composition
| 1 | Healthcare | 97.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $42.8M | 11.38% | 3,820,000 +25,000 | +0.7% | +$280K |
|
|
2
TG Therapeutics
TGTX
$4.65B
| $37.8M | 10.06% | 2,215,000 +325,000 | +17% | +$5.55M |
|
|
SLRN
3
DELISTED
ACELYRIN
SLRN
| $30.9M | 8.22% | 4,146,138 | – | – |
|
4
Rhythm Pharmaceuticals
RYTM
$6.85B
| $28M | 7.46% | 610,000 -43,000 | -7% | -$1.98M |
|
5
Ocular Therapeutix
OCUL
$2.12B
| $27.1M | 7.2% | 6,070,000 -398,000 | -6% | -$1.78M |
|
6
Catalyst Pharmaceutical
CPRX
$2.52B
| $21.4M | 5.7% | 1,257,200 +52,200 | +4% | +$890K |
|
7
Keros Therapeutics
KROS
$618M
| $14.2M | 3.78% | 357,500 -2,900 | -0.8% | -$115K |
|
8
IDEAYA Biosciences
IDYA
$2.15B
| $11.1M | 2.95% | 311,500 | – | – |
|
9
Eton Pharmaceutcials
ETON
$464M
| $11.1M | 2.95% | 2,529,887 +99,617 | +4% | +$436K |
|
10
Crinetics Pharmaceuticals
CRNX
$2.92B
| $10.9M | 2.91% | 307,500 -62,500 | -17% | -$2.22M |
|
|
11
Arvinas
ARVN
$568M
| $10.9M | 2.89% | +263,700 | New | +$10.9M |
|
|
12
Codexis
CDXS
$246M
| $9.29M | 2.47% | 3,045,525 +1,926,625 | +172% | +$5.88M |
|
|
13
Biohaven
BHVN
$1.63B
| $8.56M | 2.28% | 200,000 -239,000 | -54% | -$10.2M |
|
14
Edgewise Therapeutics
EWTX
$1.51B
| $7.65M | 2.03% | 699,000 -176,405 | -20% | -$1.93M |
|
15
Iovance Biotherapeutics
IOVA
$807M
| $7.29M | 1.94% | 897,000 +287,000 | +47% | +$2.33M |
|
|
16
Arcutis Biotherapeutics
ARQT
$1.86B
| $6.33M | 1.68% | +1,960,000 | New | +$6.33M |
|
17
4D Molecular Therapeutics
FDMT
$288M
| $6.25M | 1.66% | 308,500 | – | – |
|
|
MRNS
18
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $6.13M | 1.63% | 563,500 -20,500 | -4% | -$223K |
|
19
Vaxcyte
PCVX
$4B
| $5.65M | 1.5% | 90,000 | – | – |
|
20
Liquidia Corp
LQDA
$2.38B
| $5.35M | 1.42% | 445,000 -125,700 | -22% | -$1.51M |
|
21
Protara Therapeutics
TARA
$120M
| $5.05M | 1.34% | 2,692,594 | – | – |
|
22
UroGen Pharma
URGN
$900M
| $4.8M | 1.28% | 320,000 | – | – |
|
23
Xoma
XOMA
$392M
| $4.63M | 1.23% | 250,000 -24,500 | -9% | -$453K |
|
24
Applied Therapeutics
APLT
$71M
| $3.66M | 0.97% | 1,092,500 +199,500 | +22% | +$668K |
|
|
25
Relmada Therapeutics
RLMD
$37.2M
| $3.63M | 0.97% | 877,000 +847,000 | +2,823% | +$3.51M |
|